About This Webinar:
This webinar will discuss the possible role of prodromal schizophrenia in shaping the seminal contributions of the late John Nash to game theory and how his son’s struggle with schizophrenia motivated Nash to seek and achieve partial functional recovery, while not taking antipsychotic medication. The presentation will also address novel medications for schizophrenia and current pharmacogenetics research to guide choice of medications which could enable better outcomes in schizophrenia, and recovery from chronic severe psychosis and cognitive impairment in an exceptional patient who challenges current widely held beliefs about the mood disorder-schizophrenia spectrum.
Click anywhere in the image below to play webinar recording.
Looking for the slides from this presentation? Download them here.
Herbert Y. Meltzer, M.D.
Foundation Scientific Council Member
1992 Recipient of the Lieber Prize for Outstanding Achievement in Schizophrenia Research
NARSAD Grantee, 1988, 1994, 2000, 2007
Professor of Psychiatry and Behavioral Sciences and of Physiology
Professor of Psychiatry and Pharmacology
Northwestern Feinberg School of Medicine, Chicago, IL
Dr. Meltzer directs a multifaceted research program in schizophrenia and bipolar disorder which is devoted to developing more effective treatments. He is one of a few clinical researchers also heavily engaged in basic research. He is particularly renowned for having been the principal investigator of the seminal trials that led to the approval of clozapine for treatment-resistant schizophrenia (1988) and patients who are at high risk for suicide (2003). He also is credited with articulating the theory that atypical antipsychotics such as clozapine owe much of their advantage over typical drugs to the balance between serotonin and dopamine receptor blockade (1989). Dr. Meltzer is an active clinician who directs the clinical trial research effort at mental health centers in Chicago, IL and Cleveland, OH.
Prior to joining Northwestern, Dr. Meltzer taught at Vanderbilt University, where he also directed the Psychosis Program.
Jeffrey Borenstein, M.D.
President & CEO, Brain & Behavior Research Foundation
Jeffrey Borenstein, M.D., joined the Brain & Behavior Research Foundation in 2012 as Chief Medical Officer and was appointed as President & Chief Executive Officer at the start of 2013. Dr. Borenstein has more than two decades of experience in health and non-profit leadership. He is former CEO/Medical Director of Holliswood Hospital, where he served from 1996 to 2012. He is a board-certified psychiatrist and the Host of the award-winning series, “Healthy Minds,” which is broadcast on public television stations across the United States. He is Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association.
An active contributor to the psychiatric field for more than three decades, Dr. Borenstein currently chairs the Council on Communications of the American Psychiatric Association, the Mental Health Services Council of NY State, and the Section on Psychiatry, NY Academy of Medicine, where he is a Fellow. Among the many honors to his credit are the National Alliance on Mental Illness of NY State Connie Lieber Award, the American Psychiatric Association Special Presidential Commendation and the Federation of Organizations Community Mental Health Man of the Year Award.
Dr. Borenstein is Associate Clinical Professor of Psychiatry, Columbia University College of Physicians & Surgeons. He is a graduate of Harvard College and New York University School of Medicine.